DOI:
10.1055/s-00050348
Indian Journal of Medical and Paediatric Oncology
LinksClose Window
References
Tabernero J, Hitara K, Mansoor W, Arkenau H, Prokharau A, Alsina M. et al.
Overall survival results from a phase III trial of trifluridine/tipracial vs placebo in patients with metastatic gastric cancer refractory to standard therapies (TAGS).
Ann Oncol 2018;
29 (suppl 5; abstr) LBA-002
Access:
We do not assume any responsibility for the contents of the web pages of other providers.